688068 Stock Overview
Engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Beijing Hotgen Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.32 |
| 52 Week High | CN¥55.88 |
| 52 Week Low | CN¥23.67 |
| Beta | 1.55 |
| 11 Month Change | -1.97% |
| 3 Month Change | -15.18% |
| 1 Year Change | -37.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688068 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -1.1% | -1.4% | -2.8% |
| 1Y | -38.0% | -39.5% | -21.0% |
Return vs Industry: 688068 exceeded the CN Life Sciences industry which returned -39.5% over the past year.
Return vs Market: 688068 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 688068 volatility | |
|---|---|
| 688068 Average Weekly Movement | 4.7% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688068's share price has been volatile over the past 3 months.
Volatility Over Time: 688068's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,036 | Changqing Lin | www.hotgen.com.cn |
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd.
Beijing Hotgen Biotech Co., Ltd. Fundamentals Summary
| 688068 fundamental statistics | |
|---|---|
| Market cap | CN¥2.20b |
| Earnings (TTM) | -CN¥26.45m |
| Revenue (TTM) | CN¥454.44m |
4.8x
P/S Ratio-83.2x
P/E RatioIs 688068 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688068 income statement (TTM) | |
|---|---|
| Revenue | CN¥454.44m |
| Cost of Revenue | CN¥196.26m |
| Gross Profit | CN¥258.17m |
| Other Expenses | CN¥284.62m |
| Earnings | -CN¥26.45m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 56.81% |
| Net Profit Margin | -5.82% |
| Debt/Equity Ratio | 0% |
How did 688068 perform over the long term?
See historical performance and comparison